Rotinen Díaz, Mirja Sofia

Profile Picture

Email Address

person.page.identifierURI

https://academica-e.unavarra.es/handle/2454/49902

Birth Date

Job Title

Last Name

Rotinen Díaz

First Name

Mirja Sofia

person.page.departamento

Ciencias de la Salud

person.page.instituteName

IMAB. Research Institute for Multidisciplinary Applied Biology

ORCID

0000-0002-0755-8360

person.page.observainves

750895

person.page.upna

7847

Name

Filters

20241
Reset filters

Settings

Author: Freedland, Stephen J. × Subject: Hormonal therapy ×

Search Results

Now showing 1 - 1 of 1
  • Thumbnail Image
    PublicationOpen Access
    ONECUT2 acts as a lineage plasticity driver in adenocarcinoma as well as neuroendocrine variants of prostate cancer
    (Oxford University Press, 2024-06-27) Qian, Chen; Yang, Qian; Rotinen Díaz, Mirja Sofia; Huang, Rongrong; Kim, Hyoyoung; Gallent, Brad; Yan, Yiwu; Cadaneanu, Radu M.; Zhang, Baohui; Kaochar, Salma; Freedland, Stephen J.; Posadas, Edwin M.; Ellis, Leigh; Di Vizio, Dolores; Morrissey, Colm; Nelson, Peter S.; Brady, Lauren; Murali, Ramachandran; Campbell, Moray J.; Yang, Wei; Knudsen, Beatrice S.; Mostaghel, Elahe A.; Ye, Huihui; Garraway, Isla P.; You, Sungyong; Freeman, Michael R.; Ciencias de la Salud; Osasun Zientziak; Institute for Multidisciplinary Research in Applied Biology - IMAB
    Androgen receptor- (AR-) indifference is a mechanism of resistance to hormonal therapy in prostate cancer (PC). Here we demonstrate that ONECUT2 (OC2) activates resistance through multiple drivers associated with adenocarcinoma, stem-like and neuroendocrine (NE) variants. Direct OC2 gene targets include the glucocorticoid receptor (GR; NR3C1) and the NE splicing factor SRRM4, which are key drivers of lineage plasticity. Thus, OC2, despite its previously described NEPC driver function, can indirectly activate a portion of the AR cistrome through epigenetic activation of GR. Mechanisms by which OC2 regulates gene expression include promoter binding, enhancement of genome-wide chromatin accessibility, and super-enhancer reprogramming. Pharmacologic inhibition of OC2 suppresses lineage plasticity reprogramming induced by the AR signaling inhibitor enzalutamide. These results demonstrate that OC2 activation promotes a range of drug resistance mechanisms associated with treatment-emergent lineage variation in PC and support enhanced efforts to therapeutically target OC2 as a means of suppressing treatment-resistant disease.